Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 42, Issue 1, 2000, Pages 27-36

  Lewi, David S ^a   Suleiman, Jamal M ^b   Uip, David E ^c   Pedro, Rogerio J ^d   Souza, Rosa A ^e   Suleiman, Grace S ^b   Accetturi, Conceição ^a   Leite, Olavo M ^c   Abreu, William B ^d   Kalichman, Artur O ^e   Morales Filho, Joaquim P P ^f   Motti, Eduardo F ^f   Pecoraro, Maria Lucia C ^f   Makurath, Mark R ^f   Nessly, Michael L ^f   Leavitt, Randi Y ^f  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e Ctro Referencia e Treinamento AIDS   (Brazil)

^f NONE

Author keywords

AIDS; Clinical endpoint; Disease progression; Double blind clinical trial; HIV; Indinavir; Protease inhibitors; Randomized study; Therapy; Zidovudine

Indexed keywords

INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOLS; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 0034007440     PISSN: 00364665     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0036-46652000000100005     Document Type: Article

References (32)

1. BRITISH HIV ASSOCIATION guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee. Lancet. 349; 1086-1092, 1997.
2. CAMERON, D.W.; HEATU-CHIOZZI, M.; DAMNER, S.C. et al. - Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet, 351: 543-549, 1998.
3. CARPENTER, C.C.J.; FISCHL, M.A.; HAMMER, S.M. et al. - Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society USA panel. J. Amer. med. Ass., 277: 1962-1969, 1997.
4. CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents und adults. M.M.W.R., 41 (RR 17) December 18, 1992.
5. COOMBS, R.W., WELLES, S.L.; HOOPER. C. et al, - Association of plasma human imummodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J. infect. Dis., 174: 704-712, 1996.
6. DANNER, S.A.; CARR, A.; LEONARD, J.M. et al. - A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease, New Engl. J. Med., 333: 1528-1533, 1995.
7. DELTA: n randomized double-blind controlled trial comparing combinations of zidovudine plus didanos ne or zalcitabine with zidovodine alone in HIV-intected individuals. Delta Coordinating Committee. Lancet. 348: 283-291, 1996.
8. DEMETS, D.L. & LAN, K.K.G. - Interim analysis: the alpha spending function approach. Statist. Med. 13: 1341-1352, 1994.
9. DIVISION OF AIDS - Division of AIDS table for grading severity of adult adverse experiences. Rockville, National Institute of Allergy and Infectious Diseases. 1996.
10. ERON, J.; PETERSON, D.; MURPHY, R. et al. - An open-label. randomized, comparative study of d4T + ddI + IDV versus ZDV + 3TC + IDV in treatment naive HIV-infected patients: START II. In: CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 5., Chicago, February 1-5. 1998. Abstracts, p. 381.
11. GULICK, R.; MELLORS, J.W.; HAVLIR. D. et al. - Simultaneous versus sequential initiation of therapy for HIV-I infection, 100 week follow-up. J. Amer. med. Ass., 280: 35-41, 1998.
12. GULICK, R.M.; MELLORS, J.W.; HAVLIR. D. et al. - Treatment with indinavir, zidovudine. and lamivudine in adults with human immunodeficiency virus infection and prior ant retroviral therapy. New Engl. J. Med., 337: 734-739, 1997.
13. HAMMER, S.M.; KATZENSTEIN, D.A., HUGHES. M.D. et al. - A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter, New Engl. J, Med., 335: 1081-1090, 1996.
14. HAMMER, S.M.; SQUIRES, K.E.; HUGHES. M.D. et al. - A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and cd4 cell counts of 200 per cubic millimeter or less New Engl. J. Med., 337: 725-733, 1997.
15. HUGHES, M.D. JOHNSON, V.A.; HIRSCH, M.S. et al. - Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann. Intern. Med., 126: 929-938, 1997.
16. KAHN, J.; MAYERS. D.; RIDDLER. S. et al. - Durable clinical anti-HIV-1 activity (60 weeks) and tolerability for efavirenz (DMP266) in combination with indinavir (IDV) - suppression to "< I copy/ml." (OD=background) by Amplicor as a predictor of virologic treatment response (DMP266 - 003 Cohort IV). In; CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS. 5., Chicago. February 1-5, 1998. Abstracts. p. 692.
17. KATZENSTEIN, D.A.; HAMMER, S.M.; HUGHES. M.D. et al. - The relation of virologic and immunologic markers to clinical outcomes after nudeoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New Engl. J. Med., 335: 1091-1098, 1996.
18. MARKOWITZ, M.; SAAG, M.; POWDERLY, W. G. et al. - A preliminary study of ritonavir, an inbibitor of HIV-1 protease, to treat HIV-1 infection. New Engl. J. Med., 333: 1534-1539, 1995.
19. MATTHEWS, J.N.S.; ALTMAN, D.G.; CAMPBELL, M.J. & ROYSTON, P. - Analysis of serial measurements on medical research. Brit, med. J., 300: 230-235, 1990.
20. MELLORS, J.W.; KINGSLEY, L.A.; RINALDO, C.R. et al. - Ouantitation of HIV-1 RNA in plus na predicts outcome after seroconversion. Ann. Intern. Med., 122: 573-579, 1995.
21. MELLORS, J.W.; MUNOZ, A.; GIORGI, J.V. et al. - Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med., 126: 946-954, 1997.
22. MELLORS, J.W.; RINALDO, C.R.; GUPTA, P. et al. - Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272: 1167-1170, 1996.
23. O'BRIEN, P.C. & FLEMING, T.R. - A multiple testing procedure for clinical trials. Biometrics, 35: 549-556, 1979.
24. O'BRIEN, W. A.; HARTIGAN, P.M.; DAAR, E.S. et al. - Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann. Intern. Med., 126: 939-945, 1997.
25. PALELLA, F.J.; DELANEY, K.M.; MOORNAN, A.C. et al. - Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med., 338: 853-860, 1998.
26. RABOUD, M.; MONTANER, J.S.G.; CONWAY, B. et al. - Variation In plasma RNA levels, CD4 cell counts and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J. Infect. Dis., 174: 191-194, 1996.
27. SALGO, M.; BEATTIE, D.; BRAGMAN, K. et al. - Saquinavir (invirase, SQV) vs. HIVID (zalcitabine,ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (zidovudine, ZDV). In: INTERNATIONAL CONFERENCE ON AIDS. II., Vancouver, July 7-12, 1996. Abstracts. p. MOB410.
28. RANDOMIZED TRIAL of addition of Iamivudine or lamivudine plus loviride to zidovudine-contnining regimens for patients with HIV-1 infection: the CAESAR trial. Lancet, 349: 1413-1421, 1997.
29. SÃO PAULO (Estado). Secretaria da Saúde - Programa DST/AIDS. Bol. Epidem., 14: 3, 1996.
30. SQUIRES, K.; GULICK, R.; SANTANA. A. et al. - An open-label, randomized, comparative study of d4T + 3TC + IDV versus ZDV + 3TC + IDV in treatment naïve HIV-intected patients: START I. In: CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS. 5., Chicago, February 1-5, 1998. Abstracts, p. 380.
31. STEIN, D.; DRUNSANO, G.; STEIGBIGEL, R. et al. - Two year follow-up of patients treated with indinavir 800 mg q8h. In: CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 4., Washington, DC, January 22-26, 1997. Abstracts, p. 195
32. WELLES, S.L.; JACKSON, J.B.; YEN-LIEBERMAN, B. et al. - Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 diseases and with little or no prior zidovudine therapy. J. infect. Dis., 174: 696-703, 1996.